Novabiotics - a leading clinical-stage biotechnology company
Novabiotics about us Novabiotics clinical studies Novabiotics pipeline Novabiotics our news Novabiotics contact

Publication of NovaBiotics’ research on the host-mediated anti-viral (including against coronaviruses and influenza) and anti-inflammatory mechanism of action of cysteamine, the active component of its advanced clinical stage NM001 and NM002 product candidates for inflammatory-infectious respiratory disease.

ScienceDirect article ‘Cysteamine-mediated blockade…’